SuperworthAxogen EPS AXGN
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- −$0.68
- Latest quarter, Q2 FY26
- −$0.03
- −400% on a year earlier
- Fiscal year 2025
- −$0.34
Axogen's earnings per share was −$0.68 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.03, down 400% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.34 | n/a |
| FY2024 | −$0.22 | n/a |
| FY2023 | −$0.52 | n/a |
| FY2022 | −$0.68 | n/a |
| FY2021 | −$0.65 | n/a |
| FY2020 | −$0.60 | n/a |
| FY2019 | −$0.74 | n/a |
| FY2018 | −$0.60 | n/a |
| FY2017 | −$0.30 | n/a |
| FY2016 | −$0.46 | n/a |
| FY2015 | −$0.52 | n/a |
| FY2014 | −$0.99 | n/a |
| FY2013 | −$1.11 | n/a |
| FY2012 | −$0.84 | n/a |
| FY2011 | −$6.65 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.03 | −400% | −$0.68 | |
| Q1 FY26 | −$0.38 | n/a | −$0.64 | |
| Q4 FY25 | −$0.28 | −2900% | −$0.34 | |
| Q3 FY25 | $0.01 | n/a | −$0.05 | |
| Q2 FY25 | $0.01 | n/a | −$0.10 | |
| Q1 FY25 | −$0.08 | n/a | −$0.15 | |
| Q4 FY24 | $0.01 | n/a | −$0.22 | |
| Q3 FY24 | −$0.04 | n/a | −$0.32 | |
| Q2 FY24 | −$0.04 | n/a | −$0.38 | |
| Q1 FY24 | −$0.15 | n/a | −$0.50 | |
| Q4 FY23 | −$0.09 | n/a | −$0.52 | |
| Q3 FY23 | −$0.10 | n/a | −$0.56 |
Against its peers
Companies in Medical - Devices nearest Axogen's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| AXGNAxogen | −$0.68 | |
| TMDXTransMedics | $3.84 | +99% a year |
| CNMDCONMED | $1.85 | −48% a year |
| ITGRInteger | $3.66 | +61% a year |
| LIVNLivaNova | $3.39 | |
| ZBHZimmer Biomet | $4.11 | +0% a year |
| ELMDElectromed | $1.31 | +56% a year |
| Peer median | $3.52 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Axogen
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.